{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.18","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Urine samples were collected to assess urine Protein. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Protein excretion (24 hour) is presented.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).","id":"OG000","title":"Part 2: GSK2857916 3.40 mg/kg (NHL)"}],"paramType":"MEAN","populationDescription":"Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1 (Cycle 2)","title":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)","type":"PRIMARY","unitOfMeasure":"Grams per day"}